CPH Stock Overview
Cipher Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada.
Cipher Pharmaceuticals Inc. Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||CA$3.21|
|52 Week High||CA$3.39|
|52 Week Low||CA$1.54|
|1 Month Change||26.38%|
|3 Month Change||45.91%|
|1 Year Change||45.25%|
|3 Year Change||137.78%|
|5 Year Change||-29.45%|
|Change since IPO||-13.24%|
Recent News & Updates
Here's Why I Think Cipher Pharmaceuticals (TSE:CPH) Is An Interesting Stock
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...
|CPH||CA Pharmaceuticals||CA Market|
Return vs Industry: CPH exceeded the Canadian Pharmaceuticals industry which returned -66% over the past year.
Return vs Market: CPH exceeded the Canadian Market which returned -5.6% over the past year.
|CPH Average Weekly Movement||4.6%|
|Pharmaceuticals Industry Average Movement||12.2%|
|Market Average Movement||9.9%|
|10% most volatile stocks in CA Market||18.1%|
|10% least volatile stocks in CA Market||3.8%|
Stable Share Price: CPH is less volatile than 75% of Canadian stocks over the past 3 months, typically moving +/- 5% a week.
Volatility Over Time: CPH's weekly volatility (5%) has been stable over the past year.
About the Company
Cipher Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada. Its commercial products include Epuris (CIP-ISOTRETINOIN), a formulation of the active ingredient isotretinoin for use in the treatment of severe acne; Ozenoxacin to treat adult and paediatric patients with impetigo; Actikerall, which is indicated for the treatment of palpable or moderately thick hyperkeratotic actinic keratosis; Vaniqa, a prescription cream that reduces the growth of unwanted facial hair in women; BRINAVESS, a treatment for sinus rhythm in adults; and AGGRASTAT, an intravenous anti-platelet drug. The company’s licensed products comprise CIP-Isotretinoin; Lipofen (CIP-Fenofibrate), a formulation of the active ingredient fenofibrate used for the treatment of hyperlipidemia, a cholesterol disorder; and Conzip/Durela (CIP- Tramadol), a formulation of the active ingredient tramadol for the management of moderate to moderately severe pain.
Cipher Pharmaceuticals Inc. Fundamentals Summary
|CPH fundamental statistics|
Is CPH overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|CPH income statement (TTM)|
|Cost of Revenue||US$3.92m|
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
|Earnings per share (EPS)||0.31|
|Net Profit Margin||37.04%|
How did CPH perform over the long term?See historical performance and comparison